|
| Complement inhibitor | Medicine | Diseases | Study phase |
|
| Recombinant C1 inhibitor | Conestat alfa | HAE
Side effects: headache and allergy. | In clinical use, EU approved. |
| (Ruconest in Europe/Rhucin in USA) |
|
| Plasma-derived C1 inhibitors | Berinert P/cinryze | HAE | In clinical use, FDA approved. |
|
| C3 inhibitors | Compstatin (POT-4) | AMD | Phase II |
| Staphylococcal complement inhibitor (SCIN) | | Preclinical |
|
| Myristoylated peptidyl derived from soluble CR1 | Mirococept (APT070) | Delayed graft function of cadaveric kidney after transplantation. | Phase II |
|
| Factor H | Plasma-derived factor H concentrate | HUS, AMD | Preclinical |
| TT30/targeted alternative pathway inhibitor/factor H | PNH, AMD | Phase I |
|
| Factor D inhibitor | Anticomplement factor D | AMD | Phase II |
|
| Factor B inhibitor | TA106/anti-complement factor B | AMD | Preclinical |
|
| C5 inhibitors | Eculizumab | PNH
Side effects: headache, thrombocytopenia, gastrointestinal complaints and infections.
Before use: vaccination against meningococcal infection. | In clinical use, FDA approved. |
| Various other diseases, for example, kidney transplants, HUS, AMD. | Phase I |
| Pexelizumab | | Phase III study failed |
| Mubodina | HUS | Preclinical |
| Ergidina | Ischemia/reperfusion injury | Preclinical |
| ARC 1905 | AMD | Phase I |
|
| C5a inhibitor | PMX 53 and several other compounds | AMD | Phase II study discontinued |
| Osteoarthritis | Phase I |
|
| Targeted complement inhibitors | Targeted
(CR2 mediated) complement inhibitors | Chronic glomerulonephritis | Phase I |
|
